Related articles
Is Data Readiness Slowing Down AI in Clinical Trials? How Agentic AI Enables Immediate Impact
Most sponsors and CROs say their data isn't ready for AI. But agentic AI does not require a perfect data environment to begin delivering value. It can be deployed compliantly across siloed platforms, interpreting and reconciling differences in real time. In this 60-minute session, learn how AI agents deliver measurable value safely across clinical trials, reduce cognitive and operational burden, and enable teams to generate impact now while strengthening data foundations over time.
Real-time clinical trials are here. Medable was built for them.
Real-time clinical trials are here. Medable's continuous trial management platform gives sponsors the evidence generation, agentic AI, and regulatory-ready infrastructure to run clinical programs at the speed the FDA now expects.
Paper COAs in 2026? It’s not “cheaper,” it’s riskier
eCOA’s time has come. The market is currently estimated to be worth $2.3 billion, with projections showing it reaching nearly $5 billion by 2030. Despite this, paper still plays a prominent role for some clinical trials today.
At first glance, paper may seem simple and familiar, even economical. However, in today’s regulatory and operational environment, paper COAs are not a risk averse choice when held to the standards of what sponsors, CROs, and regulators are looking for trial data to prove.